EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Clozapine Augmentation Strategies and Clinical Predictors of Prolonged Tertiary Hospitalization in Clozapine-Resistant Schizophrenia: a Retrospective Cohort Study

Kaitlyn Baldwin, William G Honer, Reza Shahbazi, Diane Fredrikson, Randall F White, Fidel Villa-Rodriguez iD, Reza Rafizadeh iD

Schizophrenia Bulletin · 2026

DOI: 10.1093/schbul/sbag187 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Kaitlyn Baldwin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, V6T1Z3, Canada. Hauptthemen laut MEDLINE: Clozapine, Schizophrenia, Treatment-Resistant, Antipsychotic Agents, Electroconvulsive Therapy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis Clozapine-resistant schizophrenia (CRS) remains a major clinical challenge, with persistent symptoms and functional impairment despite adequate clozapine treatment. Real-world evidence is limited, and guidelines recommend a narrow set of augmentation strategies—aripiprazole (D2/3R partial agonist), amisulpride (D2/3R selective antagonist), and electroconvulsive therapy (ECT)—without clear guidance on selection or sequencing. This study examined augmentation choice and its association with length of stay (LOS) and symptomatic outcomes. Study Design We conducted a retrospective cohort study using BC Psychosis Program electronic records (2012-2025). Symptom severity and functioning scores (PANSS, CGI-S, GAPS, SOFAS) were extracted at admission and discharge. Multivariable Cox models assessed LOS for index and discharge augmentation strategies. ANCOVA compared symptom change across discharge strategies. A machine-learning model examined predictors of ECT versus pharmacological augmentation at discharge. Study Results Eighty-eight admissions were included. In adjusted index models, D2/3R selective antagonism was associated with shorter LOS than ECT (HR 2.50, 95% CI 1.35–4.62); partial agonism was not (HR 1.41, 95% CI 0.75–2.63). Partial agonist augmentation had the highest inefficacy-related switching. By discharge strategy, ECT was associated with greater reduction in positive symptoms than selective antagonism (MD −3.20, 95% CI −5.65 to −0.75) and partial agonism (MD −3.87, 95% CI −6.57 to −1.16). Greater impairment in psychosis and functioning on admission predicted ECT at discharge (AUC 0.74; balanced accuracy 0.72). Conclusions D2/3R selective antagonism was the most resource-efficient strategy, while ECT produced greater improvement in positive symptoms. Incorporating baseline psychosis severity and functioning into measurement-based care may support more informed augmentation selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineSchizophrenia, Treatment-ResistantAntipsychotic AgentsElectroconvulsive TherapyLength of StayOutcome Assessment, Health CareAmisulprideSchizophreniaHumansFemaleRetrospective StudiesMaleAdultMiddle Aged

Stichwörter der Autor:innen

ECTaugmentationclozapineschizophreniatreatment-resistance

Substanzen

ClozapineAntipsychotic AgentsAmisulpride

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, V6T1Z3, Canada.
  • Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, V6T2A1, Canada.
  • BC Psychosis Program, Vancouver, British Columbia, V6T2A1, Canada.
  • Machine Learning Engineer based in San Francisco, San Francisco, CA, United States.
  • Non-Invasive Neurostimulation Therapies Laboratory, Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, V6T2A1, Canada.
  • School of Biomedical Engineering, Faculty of Applied Science | Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, V6T1Z3, Canada.

ORCID-Profile: Fidel Villa-Rodriguez, Reza Rafizadeh

Zitieren

APA

Baldwin, K., Honer, W. G., Shahbazi, R., Fredrikson, D., White, R. F., Villa-Rodriguez, F., & Rafizadeh, R. (2026). Clozapine Augmentation Strategies and Clinical Predictors of Prolonged Tertiary Hospitalization in Clozapine-Resistant Schizophrenia: a Retrospective Cohort Study. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbag187

Vancouver

Baldwin K, Honer WG, Shahbazi R, Fredrikson D, White RF, Villa-Rodriguez F, et al. Clozapine Augmentation Strategies and Clinical Predictors of Prolonged Tertiary Hospitalization in Clozapine-Resistant Schizophrenia: a Retrospective Cohort Study. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbag187

BibTeX
@article{Baldwin2026,
  author = {Baldwin, Kaitlyn and Honer, William G and Shahbazi, Reza and Fredrikson, Diane and White, Randall F and Villa-Rodriguez, Fidel and Rafizadeh, Reza},
  title = {Clozapine Augmentation Strategies and Clinical Predictors of Prolonged Tertiary Hospitalization in Clozapine-Resistant Schizophrenia: a Retrospective Cohort Study},
  journal = {Schizophrenia Bulletin},
  year = {2026},
  doi = {10.1093/schbul/sbag187}
}
Kostenlos starten →